#Canada #Halifax #Ultrasound Therapy #Sound Blade Medical #Histotripsy

Sound Blade Medical Secures $16.5 Million Series A Funding

On January 29, 2025, Sound Blade Medical, Inc., a pioneering medical device firm specializing in handheld ultrasound-guided histotripsy technology, announced the successful closing of a $16.5 million Series A financing round. This funding round was notably oversubscribed, led by Amzak Health and Lumira Ventures, with additional participation from Invest Nova Scotia. This significant funding is aimed at speeding up the development and clinical validation of Sound Blade's innovative technology, which is expected to revolutionize the treatment of various patient conditions.

Advancing Medical Technologies
Jeremy Brown, Ph.D., Co-founder and CEO of Sound Blade Medical, expressed his enthusiasm regarding the support from these forward-thinking investors. He remarked, “This funding enables us to rapidly advance our technology, expand our team and accelerate regulatory approvals to quickly bring our therapy to patients in need.” With this financial boost, the company plans to expedite the rollout of their cutting-edge treatment solutions.

Sound Blade's histotripsy technology is a non-invasive and non-thermal ablation process. It utilizes focused ultrasound energy, delivered externally, to destroy specific targeted tissues. Instead of heating the tissues—a common concern with traditional methods—the sound waves create cavitation bubbles at the focus point of the ultrasound beam. When these bubbles collapse, they liquefy the targeted tissue, ensuring minimal risk and improved recovery outcomes.

The Potential Benefits of Histotripsy
Compared to traditional open surgery, histotripsy offers a range of compelling advantages, including reduced blood loss, fewer complications, shorter recovery times, and a lowered likelihood of infection. This non-thermal nature of histotripsy technology could also enhance patients' immune response and facilitate quicker healing, providing a vital alternative to invasive surgical techniques.

Tony Natale, MD, a partner at Amzak Health, underscored the groundbreaking nature of this technology, stating, “Sound Blade's handheld histotripsy has truly disruptive potential. We’re combining a highly accomplished founding team with an investor syndicate that has built many successful Medtech companies to unlock the full promise of this platform.” This sentiment highlights the confidence in Sound Blade’s management and innovation capability, as well as the expected impact on the Medtech landscape.

Gerry Brunk, the Managing Director at Lumira Ventures, also voiced his excitement about the investment, referencing the company's historical commitment to backing successful medical device firms in Canada. He remarked that Sound Blade's roots at Dalhousie University and Nova Scotia Health reflect an exciting investment for Lumira in the promising field of non-invasive disease treatment.

About Sound Blade Medical
Founded in 2023, Sound Blade Medical is dedicated to developing advanced, handheld histotripsy technology with unparalleled precision. The company is on a mission to improve patient outcomes by providing groundbreaking non-invasive solutions that redefine medical treatment standards. For more details, you can visit their website at Sound Blade Medical.

This new funding marks a critical step for Sound Blade Medical as they navigate the development of a technology that holds the promise of transforming patient care. As they continue to innovate, all eyes will be on how quickly they can bring their handheld histotripsy therapy to market and the profound impact it may have on patients worldwide.